Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Aug 18;17(8):e0272215. doi: 10.1371/journal.pone.0272215

Impact of COVID-19 pandemic related stressors on patients with anxiety disorders: A cross-sectional study

Till Langhammer 1,*, Carlotta Peters 1, Andrea Ertle 1, Kevin Hilbert 1, Ulrike Lueken 1
Editor: Serena Scarpelli2
PMCID: PMC9387803  PMID: 35980908

Abstract

The COVID-19 pandemic and related containment measures are affecting mental health, especially among patients with pre-existing mental disorders. The aim of this study was to investigate the effect of the first wave and its aftermath of the pandemic in Germany (March–July) on psychopathology of patients diagnosed with panic disorder, social anxiety disorder and specific phobia who were on the waiting list or in current treatment at a German university-based outpatient clinic. From 108 patients contacted, forty-nine patients (45.37%) completed a retrospective survey on COVID-19 related stressors, depression, and changes in anxiety symptoms. Patients in the final sample (n = 47) reported a mild depression and significant increase in unspecific anxiety (d = .41), panic symptoms (d = .85) and specific phobia (d = .38), while social anxiety remained unaltered. Pandemic related stressors like job insecurities, familial stress and working in the health sector were significantly associated with more severe depression and increases in anxiety symptoms. High pre-pandemic symptom severity (anxiety/depression) was a risk factor, whereas meaningful work and being divorced/separated were protective factors (explained variance: 46.5% of changes in anxiety and 75.8% in depressive symptoms). In line with diathesis-stress models, patients show a positive association between stressors and symptom load. Health care systems are requested to address the needs of this vulnerable risk group by implementing timely and low-threshold interventions to prevent patients from further deterioration.

Introduction

Fear of infection and health concerns, economic and financial uncertainty, social isolation, and familial stress are major challenges in a worldwide pandemic, possibly leading to increased psychological distress and mental health problems [1, 2]. Large parts of societies were affected and many areas of life faced restrictions by the pandemic. Concerns were quickly raised about the “collateral damage” of containment measures on mental health [3]. Only a few weeks after the outbreak of the COVID-19 pandemic, first surveys concerning its immediate psychological impact indicated extensive psychological distress in the general population [4, 5]. The most frequently reported mental health issues during the first wave of the COVID-19 pandemic were symptoms of depression, anxiety, insomnia, and distress [3, 6, 7]. It may be argued that patients with pre-existing mental disorders are particularly at risk for symptom deterioration.

Regarding risk factors, uncertainties concerning health and economic status increase psychological distress and trigger psychopathological symptoms, anxiety and depression [5, 8, 911]. Previous research suggests that social isolation increases vigilance for threat, heightens feelings of vulnerability, decreases emotion recognition ability and causes serious mental health problems [1, 12]. Having children has been associated with poor post-disaster mental health outcomes, probably because of higher stress and responsibility [13, 14]. During the pandemic, families with children responded with greater fear, anxiety and depressive symptoms [15].

The pandemic itself and the restrictions necessary to prevent harm and death are particularly challenging for people already suffering from mental illness [16]. Mental health problems prior to disasters have shown to be a main risk factor for post-disaster psychopathology [13, 17, 18]. In times of the COVID-19 pandemic, individuals with a previous mental illness reported significantly higher depression and anxiety scores, higher distress, and more health anxiety [1921]. At the same time, access to (mental) health care in Germany was restricted due to the containment measures [22].

Diathesis-stress models assume that the risk for developing symptoms of mental disorders in times of crises heightens due to the interaction between stress and specific vulnerabilities (e.g., anxiety disorders).

Patients with an anxiety disorder are prone to fear of infection and health concerns, economic and financial uncertainty. Anxiety disorders, especially social anxiety disorder and panic disorder, are associated with high intolerance of uncertainty [2325], whereas health anxiety has been related to patients with panic disorder [26, 27]. Individuals with pre-existing mental illness are especially vulnerable to losing their jobs during economic recessions, especially if they are male and have low levels of education [28]. It seems plausible to assume an association between those factors and an increase in unspecific anxiety and symptoms of social anxiety disorder, panic disorder and specific phobia.

Avoidant and safety behaviours lead to short-term relief, but long-term aggravation: According to the two-factor theory of fear acquisition [29], in the long-term avoidance behaviours maintain anxiety through negative reinforcement [30], thus leading to a vicious circle. Containment measures and the potential risk of infection have “prescribed” avoidance and safety behaviors in the general population and may have reinforced these maladaptive behaviors in patients with anxiety. Especially patients with social anxiety disorder might have been relieved in the short-term in times of a lockdown as most people had only contact to close others. Following the two-factor theory, the short-term relieve would lead to the long-term maintenance of anxiety. In addition to the (the absence of) exposure does not counteract.

Major depressive disorder and dysthymia have shown to co-occur in approximately 20% to 40% of patients with primary anxiety disorders [31]. During the COVID-19 pandemic depressions rank among the most prevalent mental health problems in the general population [32], and pre-disaster mental illness has consistently been found to be a risk factor for post-disaster depression [13]. Brown et al. reported that patients with anxiety disorders have a higher risk of developing a major depression after stressful life events [33]. In a more recent review, the authors concluded that anxiety has a negative effect on depression in terms of symptom worsening, suicidal thoughts, and long-term outcome [34].

Several studies evaluated the accuracy of these assumptions on a level of depressive symptoms and unspecific anxiety [35, 36]. In a study of Pan et al. individuals with a pre-existing mental health condition experienced no change or even a slight decrease in depressive symptoms and unspecific anxiety symptoms during the first lockdown [36]. Another study found a slight decrease in symptoms of depression and no change in anxiety symptoms during the first lockdown for individuals with pre-existing mental health conditions [35]. Several studies demonstrated higher COVID-19 related stress for individuals with an anxiety disorder and major depression [37, 38]. Bendau et al. could demonstrate the vulnerability of patients with anxiety disorder and depression for increased stress [39]. They investigated changes in COVID-19 related fear, depression, and unspecific anxiety. They used the PHQ-4, which measures anxiety and depression with two items, respectively. They differed between different kinds of anxiety diagnoses as a predictor (measured by asking participants if they had a pre-existing mental disorder). On the one hand, they found higher rates in COVID-19 fear, depression and anxiety individuals claiming to have had an pre-existing anxiety disorder. On the other hand, they observed a greater decrease of symptoms over time in patients versus non-patients.

Their study and others determine pre-existing mental disorders as a specific risk factor for symptom load in times of a lockdown. However, those studies used convenience samples without valid diagnostic procedures. For treatment purposes and prevention programs, findings need confirmation in a well-characterized clinical sample. In addition, a transdiagnostic comparison would be helpful to differentiate between different needs for different kinds of anxiety disorders.

In this study, we focused on patients that have been diagnosed clinically with standardized procedures prior to the pandemic (e.g., panic disorder, social anxiety disorder, and specific phobia). In addition to earlier studies, we evaluated the impact of pandemic related stressors on changes in unspecific anxiety and symptoms underlying panic disorder, social phobia, and specific phobia. First, even though promotion of avoidance might have a relieving effect on all patients, especially on social anxiety, we hypothesized an increase of unspecific anxiety, panic symptoms, social anxiety, and specific phobia. Second, we hypothesized depressive symptoms and the worsening of unspecific anxiety to be associated with health concerns, financial worries and pre-pandemic anxiety symptoms and depression. Amount of treatment was expected to be a negatively associated with less increase of symptoms. We expected pre-pandemic symptom severity to be a vulnerability and therefore a risk factor. Several demographic variables were included in the analyses to test for further protective and risk factors.

Method

Participants and procedure

We included patients either waiting for treatment or in treatment for anxiety disorders at the specialized outpatient unit for anxiety disorders at Humboldt-Universität zu Berlin1 who met the diagnostic criteria for primary diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or specific phobia. Patients were invited by letter to participate in this study. The clinical diagnoses were based on structured clinical interview for DSM-IV (SKID; [40]) conducted prior to study participation during the initial diagnostic procedure in the outpatient clinic. Individuals who do not fulfil the indication for outpatient treatment (acute suicidal tendency, psychotic disorders, substance dependence) are regularly excluded from admission to the outpatient clinic, and hence from this study.

We contacted all patients that received a primary diagnosis in our specialized unit for anxiety disorders in our outpatient clinic. Nineteen patients from the waiting list and 89 patients in treatment opted in for participating in future studies during the diagnostic process and therefore were contacted via postal mailings in July 2020. Forty-nine patients (response rate = 45.37%) participated. We excluded two patients from the study because they did not have a diagnosed anxiety disorder and were mistakenly contacted during the recruitment (they were in treatment for affective disorders). Participants provided written informed consent to take part in the study. We performed the study in accordance with the Declaration of Helsinki, received approval by the ethics committee of the Department of Psychology the Humboldt University of Berlin (2020–41) and pre-registered the study protocol online on drks.de (DRKS00022280).

Measurements

Patients completed a set of self-generated questions also used in a parallel survey from our group conducted in the general population [41] regarding health concerns and uncertainties, social isolation, financial worries, increased parenting, and work demands. In addition, we assessed depressive symptoms and changes in symptomatology of panic disorder, social anxiety disorder, and specific phobia. For the latter, we used well-established psychometric tests for anxiety symptoms, but changed the instructions slightly in a way that changes in symptom intensity were addressed. We also used routine data from the last routine diagnostic prior to the outbreak of the pandemic. For more detailed information and psychometrics of the questionnaires used see Supplement 1 in S1 File.

Demographic information

Patients had completed a general demographics questionnaire in the initial examination in the outpatient clinic including age, sex, education level, employment status, individual and household income, and Socio-economic status (SES).

Pre-pandemic symptom severity

Severity of anxiety symptoms before the pandemic was assessed with the Hamilton Anxiety Rating Scale (HAM-A; [42]), a clinician-based questionnaire consisting of 14 items with sufficient internal reliability [43]. A sum score of less than 18 indicates mild, 18 to 24 mild to moderate, 25 to 30 moderate to severe, and more than 30 severe anxiety symptoms. Severity of depressive symptoms before the pandemic was assessed with the revised version of Beck Depressive Inventory (BDI-II; [44]), a well-validated self-assessment with 21 items based on the DSM-IV [45].

Assessment of pandemic-related stressors

Patients completed questions on four domains: health concerns (5 items), social isolation (3 items), financial worries (4 items), and family- and work-related stress (11 items) based on a 5-point Likert scale (ranging from not at all to a lot/very much) or with yes or no. For details and assignment of items to categories, see Figs 3 and 4.

Fig 3. Questions concerning strength of stressors related to the pandemic.

Fig 3

Mean and standard deviation of all participants.

Fig 4. Questions about the relevance of stressors related to the pandemic.

Fig 4

Percentages of participants answering yes or partly.

Assessment of current depressive symptoms

Severity of depression was measured with the Patient-Health Questionnaire (PHQ-9; [46, 47]). PHQ-9 sum scores of 5, 10, 15, and 20 are associated with mild, moderate, moderately severe and severe depression. The PHQ-9 was chosen for comparability to other studies in the pandemic.

Assessment of changes in anxiety symptoms

We adapted questionnaires used during the routine diagnostics to retrospectively assess changes in symptomatology during the lockdown. For most items, we only changed the dimension of the Likert scale. We had to change some items grammatically for a meaningful adaptation of the dimensions of the Likert scale. Patients were asked to rate changes in anxiety and avoidance symptoms on a 5-point Likert scale from -2 (“a lot less”) to +2 (“a lot more”) and to refer to the period since mid of March 2020 in their answers. We added an additional answer “not applicable”, as we were only interested in changes of symptoms that were present before the pandemic. The 72 items were based on three established and validated questionnaires for anxiety disorders: The Liebowitz Social Anxiety Scale (LSAS; [48, 49]), Panic and Agoraphobia Scale (PAS; [50]), and the DSM-5 Severity Measure for Specific Phobia–Adult [51]. We will refer to those modified questionnaires as LSAS-m, PAS-m and SMSP-m. We omitted two items from the Panic and Agoraphobic Scale. One item was omitted because it is an additional item that is not included in the total score (“Did most attacks occur unexpected or expected [in dreaded situations]?”), the other because it did not fit to the rating scale and could not capture a change in the severity of a specific phobia symptom (“How important were the situations you avoided?”). Thus, the modified version of the PAS (in the following called PAS-m) consisted of 12 items. All scales were recoded to 1 to 5 for the analyses.

Data analysis

To test the first hypothesis that patients experienced an increase of symptoms of unspecific anxiety, panic symptoms, social anxiety and specific phobia one sample one-sided t-tests (H0: μ < = 3) were conducted. We calculated means for the LSAS-m, PAS-m and the SMSP-m, excluding items coded as “not applicable” (e.g. not relevant for the patients’ symptom profile). We also calculated an overall score of anxiety, which was the average of the previous mean scores.

For the second hypothesis and testing for further protective and risk factors, we conducted two forward stepwise regression analyses. The first one tested the hypothesis that COVID-19 related stress (23 items), demographic (socioeconomic status, marital status, education, job, sex and age) and clinical characteristics (amount of sessions during the pandemic, pre-pandemic anxiety and depression) affect changes in severity of the anxiety symptoms, using the computed overall mean anxiety score. The second one tested the same hypothesis on depressive symptoms. Analyses were carried out using SPSS 22.0 (IBM SPSS Statistics, New York, NY, United States). A significance level of α < .05 was considered to indicate statistical significance.

Results

Sample characteristics

Details regarding the demographic and clinical characteristics of the sample are presented in Table 1.

Table 1. Demographic and clinical characteristics of participants (N = 47).

Demographics n (%/)
Female gender 28 (60%)
Age, mean (sd) 37.30 (10.78)
Marital status
    • Single 14 (30%)
    • Married/Partnership 31 (66%)
    • Separated/Divorced 2 (4%)
Employment status
    • Unemployed 5 (11%)
    • Employed 31 (66%)
    • In training 6 (13%)
    • Other 5 (11%)
    • Work in Health Sector 6 (14%)
Housing condition
    • Alone 9 (19%)
    • With partner 23 (50%)
    • With children 12 (26%)
Socio-economic status, mean (sd) 10.51 (3.39)
    • Low SES 11 (23%)
    • Medium SES 26 (55%)
    • High SES 6 (13%)
Clinical characteristics
Diagnosed anxiety disorders
    • Panic disorder with/without agoraphobia 29 (62%)
    • Social anxiety disorder 21 (45%)
    • Specific phobias 18 (38%)
    • Comorbid depression 23 (49%)
Pre-pandemic symptom severity (HAM-A), mean (sd) 22.47 (8.46)
Pre-pandemic symptom severity (BDI-II), mean (sd) 18.42 (11.84)
Number of comorbid diagnoses
    • None 13 (28%)
    • 1 13 (28%)
    • 2 16 (34%)
    • ≥3 5 (11%)
In treatment
    • Sessions since 15th of march, mean sd 9.65 8.83
    • Yes 40 (85%)
    • No (on a waiting list for treatment) 7 (15%)

Clinical characteristics were assessed before the pandemic. HAM-A = Hamilton Anxiety Scale, BDI = Beck Depression Inventory II.

Changes in anxiety symptoms

Patients reported a significant increase in panic symptoms (PAS-m: t(44) = 4.70, p < .001, d = .85) and specific phobia (SMSP-m: t(40) = 2.4, p = .011, d = .38). Social anxiety symptoms did not increase significantly. Unspecific anxiety also increased significantly (t(46) = 2.26, p = .014, d = .41). See Fig 1 for distribution. The effect sizes for the overall increase in anxiety and phobic symptoms can be considered small [52], large effects were observed for panic symptoms.

Fig 1. Changes in anxiety symptoms during and after the first wave of the pandemic.

Fig 1

Mean scores of changes in symptoms of panic disorder, social anxiety disorder and specific phobia. Significance levels indicate difference from a mean score of three, which would be no change. The solid line within the violin plots illustrates the median, and the dashed lines show the interquartile range. ***p < .001. **p < .01. *p < .05.

Depressive symptoms

On average, patients reported depressive symptoms indicating a mild depressive syndrome (Fig 2). (M = 8.30, SD = 5.57).

Fig 2. Severity of depression symptoms during and after the first wave of the pandemic.

Fig 2

The solid line within the violin plots illustrates the median, and the dashed lines show the interquartile range.

Pandemic stressors moderating changes in anxiety symptoms and severity of depression

Figs 3 and 4 depict severity of the 23 individual stressors of the pandemic. Two multiple forward regression analyses were conducted to test if the 23 stressors of the pandemic, demographics and clinical characteristics significantly predicted patients’ changes in anxiety symptoms (average across all changes of anxiety symptoms) and severity of depression (PHQ-9 sum). The regression statistics are given in Table 2.

Table 2. Summary of hierarchical regression analysis for variables predicting changes in anxiety symptoms and severity of depression.

Β t sr2 R R2 ΔR2
Changes in anxiety symptoms
Step 1 .48 .23 .23
Job worries (12) .48 3.65** .23
Step2 .59 .35 .13
Job worries .38 3.05** .14
Pre-pandemic anxiety .37 2.91** .12
Step 3 .64 .41 .06
Job worries .38 3.11** .13
Pre-pandemic anxiety .45 3.50** .17
Divorced/separated -.25 -2.05* .06
Step 4 .68 .47 .06
Job worries (12) .35 2.94** .11
Pre-pandemic anxiety .38 3.02** .12
Divorced/separated -.26 -2.19* .06
Caring/schooling children (13) .25 2.05* .05
Severity of depression
Step 1 .75 .56 .56
Pre-pandemic depression .75 7.57*** .56
Step2 .83 .68 .12
Pre-pandemic depression .67 7.67*** .36
Relationship worries (5) .36 4.14*** .12
Step 3 .85 .72 .04
Pre-pandemic depression .62 7.25*** .34
Relationship worries (5) .37 4.45*** .13
Work in health .20 2.38* .04
Step 4 .87 .76 .04
Pre-pandemic depression .62 7.69*** .34
Relationship worries (5) .40 5.09*** .15
Work in health .26 2.85** .05
Meaningful work (16) -.20 -2.56* .04

N = 47

*p < .05.

**p < .01.

***p < .001. The numbers (in parentheses) are corresponding to items in Figs 3 and 4.

We exploratory repeated the analysis after excluding all dichotomous items with less than 10% of the participants answering the less likely characteristic (see S1 File).

The results of the first regression indicated four predictors explaining 46.5% of the variance (R2 = .47, F(4,42) = 9.12, p < .001). Two pandemic related stressors affected changes in anxiety: worries about somebody’s own work situation significantly predicted changes in anxiety symptoms (β = .35, p = .005), as did overextension with caring/schooling of children (β = .25, p = .046).

The results of the second regression indicated four predictors explaining 75.8% of the variance (R2 = .76, F(4,42) = 32.88, p < .001). While pre-pandemic depression was a significant predictor of symptom change (β = .62, p < .001), three additional pandemic related stressors were included: worries about long-term damage on social relationships significantly predicted depressive symptoms (β = .40, p < .001), as did working in the health sector (β = .26, p = .007), and the subjective meaning of someone’s own work (β = -.20, p = .014).

Demographic and clinical characteristics prior to the pandemic were also included in the multiple regression analyses. The higher pre-pandemic anxiety symptom severity, the more pronounced was the reported increase in symptoms of anxiety (baseline HAM-A–Change Score; β = .38, p = .004). In addition, being divorced or separated turned out to be a protective factor (β = -.20, p = .035). In the exploratory analysis, we excluded the items divorced/separated and as an effect of this overextension with caring/schooling of children was not significant after the first two steps of the regression anymore.

For the severity of depressive symptoms, only one risk factor showed incremental validity. Pre-pandemic symptom severity (baseline BDI-II–pandemic PHQ-9; β = .62, p < .001) turned out to predict symptom severity of depression during and after the first wave of the pandemic.

Discussion

The aim of this study was to explore the impact of the first wave of the pandemic on symptom aggravation in a clinically well-characterized sample of patients diagnosed with a primary anxiety disorder who were in treatment or on a waiting list in a German academic outpatient clinic. Findings indicate a specific increase of unspecific anxiety, panic symptoms and specific phobia symptoms, but not symptoms of social anxiety. In line with general diathesis-stress models, pandemic related stressors like worrying about one’s own job and stress through caring/schooling children led to a worsening of anxiety symptoms. Depressive symptoms (a mild depression on average) were associated with worrying about consequences for relationships, working in the health sector and meaningful work during the pandemic. In addition, demographic and clinical characteristics prior to the pandemic turned out to be important. High pre-pandemic symptom severity was identified as a risk factor for both more severe anxiety and depressive symptoms during the pandemic. Surprisingly, being divorced/separated served as a protective factor.

Previous studies [36, 37] indicated a pronounced stress reactivity in patients with a pre-pandemic mental health condition, which then decreased fast. In contrast, our study shows an increase in symptoms, related to stress after a longer period, measured late in summer 2020. However, there are several important differences to our study: we relied on diagnoses assigned by trained clinicians with structured clinical interviews prior to the pandemic (other studies relied on self-reports about pre-existing disorders), we focused on patients with a primary anxiety disorder, we assessed alterations in symptoms of social anxiety disorder, specific phobia, and panic disorder based on validated questionnaires and we incorporated a longer stress period.

Diathesis-stress models emphasize the interaction between vulnerabilities like mental disorders and stressors like the pandemic and its countermeasures. Therefore, we can assume an increase in symptoms in vulnerable groups. The results of our study confirm this assumption. However, this does not pertain to all diagnostic groups included in the present study.

Anxiety disorders especially differ concerning the stimulus that leads to intensive fear and anxiety and their cognitions that lead to a different trigger of avoidance behaviour and coping strategies, which in turn might be important for the explanation of the differential effect in this study. The decline of social interactions might have led to a temporary reduction of distress and self-deprecating metacognitions particularly in patients with social anxiety disorder, as Morrissette observed in children and adolescents with social phobia during school closures [53]. Social avoidance behaviours might therefore be a reason for the “advantage” of patients with social anxiety disorder compared with those suffering from panic disorder and specific phobia. Yet, concerns are raised that reduced exposure to social interactions will lead to increased strain and destabilization in the aftermath of the pandemic when social situations can no longer be avoided [54]. This should be addressed by future studies on the medium- to long-term consequences of the pandemic.

Exogenous stressors–like the challenging life circumstances during a public health emergency–are at least partially responsible for the high prevalence of stress-related mental disorders like anxiety, mood disorders, or post-traumatic stress disorder around the world [55, 56]. The crucial role of stress on mental health in the pandemic is also evident in patients with pre-existing anxiety disorders. Greater COVID-19 related stress was associated with greater increase in symptoms of anxiety and severity of depression. Those stressors, particularly job insecurities and parental stress, combined with pre-pandemic symptom severity could explain approximately half of the variance in changes in anxiety symptoms. In a similar vein, work demands and worries about relationships negatively affected the development of depressive symptoms. Work is an essential resource in everyday life and promotes mental health. In addition, family is supposed to be a resource and social support. Both, work circumstances and familial interactions changed for many people in a stressful manner. Parents had to work from home and at the same time support their children with home schooling. From a clinical perspective, reducing existential stressors by corona aid packages given by governments are not only protecting the economy but may also promote mental health. Health-economic evaluations could help in quantifying the impact of corona aid given by governments on mental health and life quality.

Stressful negative life events, including interpersonal conflicts, financial hardships, or illness, often precede the onset of anxiety disorders [57]. There is less evidence on whether chronic stress contributes to maintaining or increasing anxiety disorders. Wade et al. report that patients with panic disorder with agoraphobia had less of an improvement from treatment when experiencing chronic stress [58]. The results of our study fit this picture, confirming the relation between stress and increases in anxiety symptoms, and furthermore underline that this patient group may be particularly vulnerable to the psychosocial consequences of a pandemic.

To facilitate coping with stress and to mitigate its effect on mental health, it is important to identify protective factors. Factors potentially buffering the effect of the COVID-19 pandemic on mental health in the general population include availability of up-to-date information, a stable and secure income, self-efficacy, and a positive appraisal style [5, 5961]. Results of our study indicate that meaningful work can mitigate the effect of the pandemic on depressive symptoms of individuals with anxiety disorders. However, no other assumed protective factors gained significance in mitigating increases in anxiety symptoms. In contrast, being divorced or separated, anticipated as a risk factor, turned out to be protective. As only two participants were divorced or separated, this finding should be regarded with caution.

Strength and limitations

Although presenting a well-defined clinical sample, results presented in this study are based on a limited number of patients and may not generalize to other anxiety disorders. It may however be assumed that patients with a general anxiety disorder might be particularly vulnerable, as worries about negative consequences are the main symptom of general anxiety disorder and a main reason for increases of symptoms in our study.

Second, although pre-pandemic information about the symptom severity was available, a direct comparison of pre-pandemic and pandemic symptom severity was not meaningful. The period between measurement of pre-pandemic symptom severity and pandemic onset varied substantially. As most of the participants were in treatment this period was confounded with possible symptom changes through treatment. Still, we believe it is a straightforward approach to include both, those in treatment and patients on the waiting list as the pandemic affected the treatment and being on the waiting list. Treatment in some cases switched to online sessions or was disrupted for a longer period because of the restrictions and missing resources for online sessions. Numbers of sessions that varied extensively did not contribute to changes in our statistical model. In some way, the worsening of symptoms seemed to be independent of treatment as usual. Specific interventions in times of crisis seem necessary.

We asked patients to focus on perceived changes in symptomatology due to the pandemic only. Thus, the study has the usual limitation of a cross-sectional study and retrospective assessment (e.g. recall bias): We cannot assume a causal relationship between the variables stress and psychological outcome. Longitudinal studies will have to confirm the findings of this study and replicate the effect of long-term stressors of the pandemic on anxiety and depressive symptoms.

Third, the small sample size in combination with a relatively large amount of predictors in the regression analyses may bear a tendency towards overestimation of explained variance. In our explorative analysis, two predictors, namely being divorced/separated and overextension with caring/schooling of children did not play a role in the best fitting model anymore. These variables should be interpreted with caution.

However, in contrast to other COVID-related studies, we here provide clinical data from actual patients and not a convenience sample from the population. Rendering the data applicable and meaningful to the clinical context. Another strength of this study is that we investigated change in specific symptoms of anxiety disorders rather than examining anxiety in general.

Conclusion

We found that individuals with anxiety disorders experienced a pronounced increase in anxiety and depressive symptoms, which was largely explained by COVID-19 pandemic related stress. Of note, this was not applicable to social anxiety, possibly indicating a short-term relief due to “prescribed” containment measures.

This study highlights the psychological impact of the pandemic and its psychosocial consequences on the vulnerable group of anxiety disorders that represent the largest group pf mental disorders in the general population and in outpatient treatment. It further emphasized the prominent role of stressors caused by the pandemic for symptom aggravation. Evidencing the validity of the vulnerability-stress-model for the current situation, a pronounced and sustained increase in patients with new incident or relapsing mental disorders should be anticipated, which is also demonstrated by current epidemiological data on a sharp global increase in the prevalence of depressive and anxiety disorders [7]. Health-care systems are required to provide timely and efficient treatment options either for the indicated prevention of mental disorders, their acute treatment or relapse prevention. Further research is required to track the psychological long-term impact of the pandemic for patients and societies.

Supporting information

S1 File

(DOCX)

Data Availability

Data cannot be shared publicly as this is not included in the informed consent by patients. The study was reviewed by the Research Ethics Committee of the Department of Psychology at Humboldt-Universtät zu Berlin, Germany (proposal number: 2020-41) and the Ethics Committee demands those strict data sharing plans in case we include patients from our outpatient clinic. Further, the dataset provides health-related data which is considered particularly sensitive data according to German data protection acts. However, deidentified participant data with annotations will be made available to other researchers upon reasonable request (towards the study administration at coro-na-stressfrei.psychologie@hu-berlin.de).

Funding Statement

The article processing charge was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) in the form of a grant (#491192747), and the Open Access Publication Fund of Humboldt-Universität zu Berlin in the form of a grant to TL. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bavel JJV, Baicker K, Boggio PS, Capraro V, Cichocka A, Cikara M, et al. Using social and behavioural science to support COVID-19 pandemic response. Nat Hum Behav. 2020; doi: 10.1038/s41562-020-0884-z [DOI] [PubMed] [Google Scholar]
  • 2.Mertens G, Gerritsen L, Duijndam S, Salemink E, Engelhard IM. Fear of the coronavirus (COVID-19): Predictors in an online study conducted in March 2020. J Anxiety Disord. 2020;74(April):102258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rajkumar RP. COVID-19 and mental health: A review of the existing literature. Asian J Psychiatry. 2020. Aug; 52: 102066. doi: 10.1016/j.ajp.2020.102066 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Qiu J, Shen B, Zhao M, Wang Z, Xie B, Xu Y. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. Gen Psychiatry. 2020. Apr 1;33(2): e100213. doi: 10.1136/gpsych-2020-100213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wang C, Pan Ri, Wan X, Tan Y, Xu L, Ho CS, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health. 2020;17(5). doi: 10.3390/ijerph17051729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wu T, Jia X, Shi H, Niu J, Yin X, Xie J, et al. Prevalence of mental health problems during the COVID-19 pandemic: A systematic review and meta-analysis. J Affect Disord. 2021. Feb;281:91–8. doi: 10.1016/j.jad.2020.11.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet. 2021. Oct; S0140673621021437. doi: 10.1016/S0140-6736(21)02143-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Forte G, Favieri F, Tambelli R, Casagrande M. The Enemy Which Sealed the World: Effects of COVID-19 Diffusion on the Psychological State of the Italian Population. J Clin Med. 2020;9(6):1802. doi: 10.3390/jcm9061802 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gonza G, Burger A. Subjective Well-Being During the 2008 Economic Crisis: Identification of Mediating and Moderating Factors. J Happiness Stud. 2017;18(6):1763–97. [Google Scholar]
  • 10.Deaton A. The financial crisis and the well-being of Americans. Oxf Econ Pap. 2012;64(1):1–26. doi: 10.1093/oep/gpr051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cheng GHL, Chan DKS. Who suffers more from job insecurity? A meta-analytic review. Appl Psychol. 2008;57(2):272–303. [Google Scholar]
  • 12.Meléndez JC, Satorres E, Reyes-Olmedo M, Delhom I, Real E, Lora Y. Emotion recognition changes in a confinement situation due to COVID-19. J Environ Psychol. 2020. Dec;72:101518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Goldmann E, Galea S. Mental health consequences of disasters. Annu Rev Public Health. 2014;35:169–83. doi: 10.1146/annurev-publhealth-032013-182435 [DOI] [PubMed] [Google Scholar]
  • 14.Norris FH. Methods for Disaster Mental Health Research. Psychiatric Services. Guilford Press; 2006. [Google Scholar]
  • 15.Fitzpatrick KM, Harris C, Drawve G. Fear of COVID-19 and the Mental Health Consequences in America. Psychol Trauma Theory Res Pract Policy. 2020; doi: 10.1037/tra0000924 [DOI] [PubMed] [Google Scholar]
  • 16.Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020. Apr 1;7(4): e21. doi: 10.1016/S2215-0366(20)30090-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Katz CL, Pellegrino L, Pandya A, Ng A, DeLisi LE. Research on psychiatric outcomes and interventions subsequent to disasters: a review of the literature. Psychiatry Res. 2002. Mar 25;110(3):201–17. doi: 10.1016/s0165-1781(02)00110-5 [DOI] [PubMed] [Google Scholar]
  • 18.Math SB, John JP, Girimaji SC, Benegal V, Sunny B, Krishnakanth K, et al. Comparative Study of Psychiatric Morbidity among the Displaced and Non-Displaced Populations in the Andaman and Nicobar Islands following the Tsunami. Prehospital Disaster Med. 2008;23(1):29. doi: 10.1017/s1049023x00005513 [DOI] [PubMed] [Google Scholar]
  • 19.Alonzi S, La Torre A, Silverstein MW. The Psychological Impact of Preexisting Mental and Physical Health Conditions During the COVID-19 Pandemic. Psychol Trauma Theory Res Pract Policy. 2020;12:236–8. doi: 10.1037/tra0000840 [DOI] [PubMed] [Google Scholar]
  • 20.Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020;66(5):504–11. doi: 10.1177/0020764020927051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Newby JM, O’Moore K, Tang S, Christensen H, Faasse K. Acute mental health responses during the COVID-19 pandemic in Australia. PloS One. 2020;15(7): e0236562. doi: 10.1371/journal.pone.0236562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Brakemeier EL, Wirkner J, Knaevelsrud C, Wurm S, Christiansen H, Lueken U, et al. Die COVID-19-Pandemie als Herausforderung für die psychische Gesundheit. Zeitschrift für Klinische Psychologie und Psychotherapie. 2020. 1–31 p. [Google Scholar]
  • 23.Carleton RN. Into the unknown: A review and synthesis of contemporary models involving uncertainty. J Anxiety Disord. 2016;39:30–43. doi: 10.1016/j.janxdis.2016.02.007 [DOI] [PubMed] [Google Scholar]
  • 24.Carleton RN, Duranceau S, Freeston MH, Boelen PA, McCabe RE, Antony MM. ‘But it might be a heart attack’: Intolerance of uncertainty and panic disorder symptoms. J Anxiety Disord. 2014;28(5):463–70. doi: 10.1016/j.janxdis.2014.04.006 [DOI] [PubMed] [Google Scholar]
  • 25.Counsell A, Furtado M, Iorio C, Anand L, Canzonieri A, Fine A, et al. Intolerance of uncertainty, social anxiety, and generalized anxiety: Differences by diagnosis and symptoms. Psychiatry Res. 2017;252(February):63–9. [DOI] [PubMed] [Google Scholar]
  • 26.Schmidt NB, Joiner TE, Staab JP, Williams FM. Health perceptions and anxiety sensitivity in patients with panic disorder. J Psychopathol Behav Assess. 2003;25(3):139–45. [Google Scholar]
  • 27.Abramowitz JS, Olatunji BO, Deacon BJ. Health Anxiety, Hypochondriasis, and the Anxiety Disorders. Behav Ther. 2007;38(1):86–94. doi: 10.1016/j.beth.2006.05.001 [DOI] [PubMed] [Google Scholar]
  • 28.Evans-Lacko S, Knapp M, McCrone P, Thornicroft G, Mojtabai R. The Mental Health Consequences of the Recession: Economic Hardship and Employment of People with Mental Health Problems in 27 European Countries. PLoS ONE. 2013;8(7). doi: 10.1371/journal.pone.0069792 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mowrer O. Learning theory and behavior. John Wiley & Sons Inc; 1960. [Google Scholar]
  • 30.Antony MM, Federici A, Stein MB. Overview and Introduction to Anxiety Disorders. Oxf Handb Anxiety Relat Disord. 2008;(June 2020):1–23. [Google Scholar]
  • 31.Huppert JD. Anxiety Disorders and Depression Comorbidity. In: Antony MM, Stein MB, editors. Oxford Handbook of Anxiety and Related Disorders. Oxford University Press; 2009. P. 576–87. [Google Scholar]
  • 32.Jones EAK, Mitra AK, Bhuiyan AR. Impact of COVID-19 on mental health in adolescents: A systematic review. Int J Environ Res Public Health. 2021;18(5):1–9. doi: 10.3390/ijerph18052470 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Brown GW, Bifulco A, Harris T, Bridge L. Life stress, chronic subclinical symptoms and vulnerability to clinical depression. J Affect Disord. 1986;11(1):1–19. doi: 10.1016/0165-0327(86)90054-6 [DOI] [PubMed] [Google Scholar]
  • 34.Goldberg D, Fawcett J. The Importance of Anxiety in both Major Depression And Bipolar Disorder: Importance of Anxiety in MDD and GAD. Depress Anxiety. 2012. Jun;29(6):471–8. doi: 10.1002/da.21939 [DOI] [PubMed] [Google Scholar]
  • 35.O’Connor RC, Wetherall K, Cleare S, McClelland H, Melson AJ, Niedzwiedz CL, et al. Mental health and well-being during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. Br J Psychiatry. 2020;1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Pan K yu, Kok AAL, Eikelenboom M, Horsfall M, Jörg F, Luteijn RA, et al. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. Lancet Psychiatry. 2020;8(2):121–9. doi: 10.1016/S2215-0366(20)30491-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Asmundson GJG, Paluszek MM, Landry CA, Rachor GS, McKay D, Taylor S. Do pre-existing anxiety-related and mood disorders differentially impact COVID-19 stress responses and coping? J Anxiety Disord. 2020. Aug;74:102271. doi: 10.1016/j.janxdis.2020.102271 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Taylor S, Asmundson GJG. Life in a post-pandemic world: What to expect of anxiety-related conditions and their treatment. J Anxiety Disord. 2020;72(May):102231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Bendau A, Kunas SL, Wyka S, Petzold MB, Plag J, Asselmann E, et al. Longitudinal changes of anxiety and depressive symptoms during the COVID-19 pandemic in Germany: The role of pre-existing anxiety, depressive, and other mental disorders. J Anxiety Disord. 2021. Apr;79:102377. doi: 10.1016/j.janxdis.2021.102377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Wittchen HU, Zaudig M, Fydrich T. Strukturiertes Klinisches Interview für DSM-IV. Achse I und II. Hogrefe; 1997. [Google Scholar]
  • 41.Hilbert K, Boeken O, Asbrand J, Seemann S, Langhammer T, Praxl B, et al. Who is seeking help for psychological distress associated with the COVID-19 pandemic? Characterization of risk factors in 1269 participants accessing low-threshold psychological help. Benetreau Y, editor. PLOS ONE. 2022. Jul 18;17(7): e0271468. doi: 10.1371/journal.pone.0271468 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety. 2001;13(4):166–78. [PubMed] [Google Scholar]
  • 43.Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61–8. doi: 10.1016/0165-0327(88)90072-9 [DOI] [PubMed] [Google Scholar]
  • 44.Beck AT, Steer RA, Brown G. Beck Depression Inventory–II. Psychol Assess. 1996; [Google Scholar]
  • 45.Kühner C, Bürger C, Keller F, Hautzinger M. Reliabilität und validität des revidierten Beck- Depressionsinventars (BDI-II). Befunde aus deutschsprachigen stichproben. Nervenarzt. 2007;78(6):651–6. doi: 10.1007/s00115-006-2098-7 [DOI] [PubMed] [Google Scholar]
  • 46.Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. Validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258–66. doi: 10.1097/00006842-200203000-00008 [DOI] [PubMed] [Google Scholar]
  • 48.Liebowitz MR. Social Phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–73. doi: 10.1159/000414022 [DOI] [PubMed] [Google Scholar]
  • 49.Stangier U, Heidenreich T. Die Liebowitz Soziale Angst-Skala (LSAS). Beltz PVU; 2004. [Google Scholar]
  • 50.Bandelow B. Panic and Agoraphobia Scale (PAS). Hogrefe & Huber Publishers; 1999. [Google Scholar]
  • 51.Lebeau RT, Glenn DE, Hanover LN, Beesdo-Baum K, Wittchen HU, Craske MG. A dimensional approach to measuring anxiety for DSM-5: Dimensional measurement of anxiety for DSM-5. Int J Methods Psychiatr Res. 2012. Dec;21(4):258–72. doi: 10.1002/mpr.1369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Academic Press; 1988. [Google Scholar]
  • 53.Morrissette M. School Closures and Social Anxiety During the COVID-19 Pandemic. J Am Acad Child Adolesc Psychiatry. 2021;60(1):6. doi: 10.1016/j.jaac.2020.08.436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Loades ME, Chatburn E, Higson-sweeney N, Reynolds S, Shafran R, Brigden A, et al. Rapid Systematic Review: The Impact of Social Isolation Adolescents in the Context of COVID-19. J Am Acad Child Adolesc Psychiatry. 2020;59(11):1218–39. doi: 10.1016/j.jaac.2020.05.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Kalisch R, Baker DG, Basten U, Boks MP, Bonanno GA, Brummelman E, et al. The resilience framework as a strategy to combat stress-related disorders. Nat Hum Behav. 2017;1(11):784–90. doi: 10.1038/s41562-017-0200-8 [DOI] [PubMed] [Google Scholar]
  • 56.Pêgo JM, Sousa JC. Stress and the Neuroendocrinology of Anxiety Disorders. In: Stein MB, Steckler T, editors. Behavioral Neurobiology of Anxiety and Its Treatment. Springer Berlin; Heidelberg; 2009. [Google Scholar]
  • 57.Manfro GG, Otto MW, McArdle ET, Worthington JJ, Rosenbaum JF, Pollack MH. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord. 1996;41(2):135–9. doi: 10.1016/s0165-0327(96)00081-x [DOI] [PubMed] [Google Scholar]
  • 58.Wade S, Monroe S, Micelson L. Chronic life stress and treatment outcome in agoraphobia with panic attacks. Am J Psychiatry. 1993;150:1491–5. doi: 10.1176/ajp.150.10.1491 [DOI] [PubMed] [Google Scholar]
  • 59.Cao W, Fang Z, Hou G, Han M, Xu X, Dong J. The psychological impact of the COVID-19 epidemic on college students in China. Psychiatry Res. 2020;287:112934. doi: 10.1016/j.psychres.2020.112934 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Veer IM, Riepenhausen A, Zerban M, Wackerhagen C, Puhlmann LMC, Engen H, et al. Psycho-social factors associated with mental resilience in the Corona lockdown. Transl Psychiatry. 2021;11(1). doi: 10.1038/s41398-020-01150-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Xiao H, Zhang Y, Kong D, Li S, Yang N. The Effects of Social Support on Sleep Quality of Medical Staff Treating Patients with Coronavirus Disease 2019 (COVID-19) in January and February 2020 in China. Med Sci Monit Int Med J Exp Clin Res. 2020;26: e923549. doi: 10.12659/MSM.923549 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Serena Scarpelli

28 Mar 2022

PONE-D-21-37020Impact of COVID-19 pandemic related stressors on patients with anxiety disorders: A cross-sectional studyPLOS ONE

Dear Dr. Langhammer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Although your manuscript was found to be of interest, I am unable to accept it in its current form.  The manuscript required major revisions that directly address the concerns of the reviewers. Specifically, the authors should improve the abstract, the introduction and clarify some methodological aspects. 

Please submit your revised manuscript by May 12 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Serena Scarpelli

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors investigated the impact of COVID-19 pandemic-related stressors on patients with anxiety disorders. Main limitation is a small sample size (49 patients). To find protective or risk factors for symptom severity for anxiety disorder, substantial changes in research methods are needed.

The abstract should include more specific results, including actual values and percentages.

Page 7

We contacted 19 patients from the waiting list and 89 patients in treatment via post in July 2020. Forty-nine patients (response rate = 45.37%) participated. We excluded two patients from the study because they did not have a diagnosed anxiety disorder.

- Patient selection is unclear. It should be clear how many patients were initially selected. Why were patients other than those with anxiety disorders included first?

Reviewer #2: The study looks at the impact of the pandemic on patients with anxiety disorders. The study thus contributes to a better understanding of the impact on this already vulnerable group and to identifying appropriate therapeutic implications.

However, the manuscript has some weaknesses, which I would like to point out below with questions for the authors.

Introduction in general: It would be great for the importance of the manuscript if the authors emphasised again at the end of the introduction why the question is important/novel.

Line 116: why were 19 people from the waiting list contacted. Then 7 people were included in the calculations. Wouldn't it be important to exclude these persons, since they had no therapeutic support during this time and thus differ substantially from the other persons in terms of support during this time? How do the authors justify these 7 persons or why were these 7 persons included?

Line 141: I am still not entirely clear whether the individual domains of the stressors should be considered coherently or whether the items simply stand alone and thus a statement on reliability is not necessary.

If one looks at the individual items, then for some questions it could also lead to an item having to be answered with "does not apply" (e.g. “worried about job situation” cannot be answered if one is already unemployed. “schooling of my child” cannot be answered if one does not have a child). Was there such an answer category? if not, how do the authors deal with the fact that some items, which are also later in the regression, could possibly not be answered correctly?

Line 149 ff: can the authors say something about the validity and reliability of the adapted questionnaires? The answer category was changed for this study and it would be good for the reader if there were more psychometric information.

This is especially important for the PAS-m, where 2 items were also removed.

Line 222 ff: it is not clear to me how the 23 stressors were included in the regression. The figures show only 4 at a time and it is not clear from the text how they were chosen and also why this order was chosen

e.g. in the first regression one would expect “pre-pandemic anxiety” to be included first.

If all 23 predictors were included, this is also not permissible due to the sample size.

It would be imperative for the understanding and interpretation of the results if the authors would present this regression in a little more detail or explain how they proceeded here (which predictors, why this order).

It would also be very welcome if it were clear to the reader exactly which predictors in the regression correspond to which items from Figures 3a and 3b. This is not possible at the moment.

Line 258/259: I am not sure how profound this statement is, as only 2 people were divorced/separated at all. This has already been included in the limitations, but this seems insufficient to me under the fact that it is so small, as it is strongly shown as a protective factor here.

Line 342 ff: The small sample size seems to be a limitation as well as the fact that it is a sample that was already in treatment. It is important to mention this, especially because the authors point out the practical implications that treatment options should be provided. However, this sample was in treatment and the authors should discuss again in detail what effect the treatment had on the increase. Did the therapists already react to this in treatment? How long were the individuals in treatment for, or how often were there therapy sessions during this time, or was therapy interrupted and this could have been an explanation for the increase?

Minor comments:

In line 76: would it be possible to find a more recent source?

Lines 79, 83: According to the journal's guidelines, is the year given in this form of citation? Otherwise, only a number is given here.

Line 90: Here it would be helpful to know in whom higher rates were found.

Line 108/109: it would be great for understanding if the German designation could be translated.

Line 194: it would also be interesting to know the burden of the patients at the time of admission with regard to anxiety symptoms in order to get an idea of how burdened the persons were.

Table 1:

Under the subcategory "Employment status", was there also a question about working in the "health sector" or did this answer come from the stressors?

Under the upper category "Domiciliary status", only the category "with partner" and "with children" was possible, or could one also tick "with partner and children"?

Under this category, 100% does not come up either.

In the upper category SES, the last line says (3.39%). Something seems to have slipped here.

Figure 2:

The first wave was already in March/April and therefore already over in July. It is therefore difficult to say that this was the symptom severity during the first wave (as described in the title of the figure). In July, the incidences had already been very low.

Reviewer #3: The manuscript "Impact of COVID-19 pandemic related stressors on patients with anxiety disorders: A cross sectional study" presents an interesting investigation in which the effect of the first wave of the COVID-19 pandemic on stress, depression and anxiety in patients diagnosed with different pathologies (panic disorder, social phobia and specific phobia) is analyzed. The results show a positive association between stressors and symptom load.

The introduction is correct; please add the following reference (page 3 line 33) which discusses the change in emotions that occurred in the first wave comparing two groups and points out the increase in depressive states due to the pandemic: Meléndez, J. C., Satorres, E., Reyes-Olmedo, M., Delhom, I., Real, E., & Lora, Y. (2020). Emotion recognition changes in a confinement situation due to COVID-19. Journal of Environmental Psychology, 72, 101518. https://doi.org/10.1016/j.jenvp.2020.101518

Measurements. Line 127. the authors note that: “For the latter, we changed the instructions of well-established psychometric tests for anxiety symptoms in a way that we ask for changes instead of intensity of symptoms.” It might be interesting for the authors to include an example of the modification.

Please provide more information on the Beck Depressive Inventory (Similar to Hamilton: internal reliability, scoring scale, cut-off points...). Please also provide information on how the Hamilton is scored: for example, "Each item is scored on a scale of 0 (not present) to 4 (severe)". Please add these characteristics to all scales used in the manuscript.

Although it is not necessary to include it in the manuscript, a question that arises in my mind is Why you did not use the same scale to assess depression during pre-pandemic and during pandemic? (BDI-II vs PHQ-9)

Regarding the modified questionnaires, I understand that what you have done is clinically correct, it is a good idea. However, it would be interesting if you could provide, if possible, information on the reliability of the modified questionnaires, this data would ensure that the modification would have been statistically correct.

In data analysis (page 9 line 166) you report: first hypothesis ..., second hypothesis. Please, when you state your research objectives at the end of the introduction, could you please match this numbering of hypotheses.

The results are correct. The explanatory figures provide the information in a satisfactory way and the regression analyses include all the necessary information.

The conclusions are correct and in accordance with the results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Serena Scarpelli

6 Jul 2022

PONE-D-21-37020R1Impact of COVID-19 pandemic related stressors on patients with anxiety disorders: A cross-sectional studyPLOS ONE

Dear Dr. Langhammer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Before acceptance, the manuscript needs some additional revisions, as suggested by reviewer 2.

Please submit your revised manuscript by Aug 20 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Serena Scarpelli

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for reviewing the comments. This has greatly helped to make the manuscript more understandable and of higher quality.

In the light of the revision, two important aspects arise that I would require to be answered.

1) The authors have stated that they have calculated a regression. My question at this point is: you included about 30 variables in the regression with a sample size of N = 47. This seems to me to be a very exploratory approach and my question is whether this number of variables is statistically justified?

Additionally, it would be great if in the methods section under statistical analyses it is still described that only significant variables are presented and all others are omitted here. It would also be interesting to know in which step which variable was included.

2) You wrote in your hypotheses/aims at the beginning (Introduction section) that you want to include health concerns, financial worries and pre-pandemic symptom severity as well as some socio-demographic variables to answer your question (regression analyses). But in the regression you find mainly variables of COVID-related stressors (number 12, 13, 5 and 16), which are not named in the hypothesis. Here I would like it to be clearer why the authors included these stressors in the analyses but did not mention them as variables to reach the aim at the end of the introduction.

Thank you so much for your effort and your great work!

Reviewer #3: The authors have correctly included the reviewers' suggestions and the manuscript has been improved.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 2

Serena Scarpelli

15 Jul 2022

Impact of COVID-19 pandemic related stressors on patients with anxiety disorders: A cross-sectional study

PONE-D-21-37020R2

Dear Dr. Langhammer,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Serena Scarpelli

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Acceptance letter

Serena Scarpelli

9 Aug 2022

PONE-D-21-37020R2

Impact of COVID-19 pandemic related stressors on patients with anxiety disorders: A cross-sectional study

Dear Dr. Langhammer:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Serena Scarpelli

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Attachment

    Submitted filename: SfA_Langhammer_Response_220510.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Data cannot be shared publicly as this is not included in the informed consent by patients. The study was reviewed by the Research Ethics Committee of the Department of Psychology at Humboldt-Universtät zu Berlin, Germany (proposal number: 2020-41) and the Ethics Committee demands those strict data sharing plans in case we include patients from our outpatient clinic. Further, the dataset provides health-related data which is considered particularly sensitive data according to German data protection acts. However, deidentified participant data with annotations will be made available to other researchers upon reasonable request (towards the study administration at coro-na-stressfrei.psychologie@hu-berlin.de).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES